Genomic ascertainment of PALB2-related cancer predisposition
In brief
PALB2 carriers had about 60% higher mortality and more cancers
In two population-based cohorts, people with a harmful PALB2 variant had higher odds of cancer overall, female breast cancer and pancreatic cancer, and 61% to 67% higher all-cause mortality than non-carriers. Survival after cancer diagnosis was also lower, but estimated risks were below those reported in family-history-based studies, highlighting how the route to identifying carriers affects risk estimates.
- Journal
- Journal of the National Cancer Institute (Q1)
- Published
- 17 November 2026
- Study design
- Case-control study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Douglas R Stewart, Jung Kim, Jeremy S Haley, Jiang Li, Michael R Sargen, Hyokyoung Hong, et al.
- PMID
- 43046605
- DOI
- 10.1093/jnci/djag429
Why clinicians should know about it
- Picked for Genetics (clinical) (paper of the day, 22 November 2026): Population-based PALB2 penetrance and mortality inform cancer-risk counseling
Abstract
BACKGROUND: Cancer risk arising from a germline pathogenic PALB2 variant ascertained through a personal or family history of cancer has been well-studied. Here, we used genomic ascertainment to quantify PALB2-associated cancer risk, age-specific penetrance, all-cause and cancer-specific mortality. METHODS: We conducted a case-control study in two large population-based adult cohorts: the UK Biobank (n = 469,580) and Geisinger MyCode (n = 167,050). PALB2 P/LP heterozygotes were identified via exome sequencing and compared with non-carriers. Cancer diagnoses and vital status were obtained from linked registry and electronic health record data. We used multivariable logistic regression to estimate odds ratios for cancer outcomes and Cox proportional hazards models to estimate hazard ratios for all-cause mortality. Age-specific cumulative incidence (penetrance) was estimated using Kaplan-Meier methods. Models were adjusted for birth year, sex (when applicable), smoking status, and body mass index. RESULTS: PALB2 P/LP variant prevalence was 1:571 in UK Biobank and 1:940 in MyCode, with the higher prevalence in the UK cohort driven by the PALB2 p.Trp1038Ter founder variant. Compared with non-carriers, heterozygotes had significantly increased odds of any cancer, female breast cancer and pancreatic cancer, in both cohorts (P < 0.01). Adjusted hazard ratios for any cancer and female breast cancer ranged from 1.7 to 3.6. All-cause mortality was increased among PALB2-heterozygotes (HR 1.61-1.67), and survival after cancer diagnosis was reduced. Family history further modified cancer risk. CONCLUSIONS: Genomic ascertainment of PALB2-heterozygotes identifies elevated risk for multiple cancers and increased all-cause and cancer-specific mortality, although risks were lower than estimates from familial ascertainment.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.